Improved uptake and retention of lipophilic prodrug to improve treatment of HIV

Advanced Drug Delivery Reviews

Volumn 39, Issue 1-3, 1999, Pages 165-182

  Yatvin, Milton B ^a   Li, Wei ^a   Meredith, Michael J ^b   Shenoy, Mohan A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

AIDS; Antiviral; Blood brain barrier; Testicular barrier; Viral reservoirs

Indexed keywords

BIOSYNTHESIS; CHEMICAL BONDS; PHARMACOKINETICS; VIRUSES;

HUMAN IMMUNODEFICIENCY VIRUS (HIV);

CONTROLLED DRUG DELIVERY;

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CERAMIDE; DIDANOSINE; ESTER; PHOSPHATIDYLCHOLINE; PRODRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; BRAIN; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG RETENTION; DRUG UPTAKE; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; LIPOPHILICITY; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; TESTIS; THYMUS; VIRUS INFECTION;

EID: 0032820953     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00025-3     Document Type: Article

References (52)

1. Meltzer M.S., Skillman D.R., Gomatos P.J., Kalter D.C., Gendelman H.E. Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Ann. Rev. Immunol. 8:1990;169-194.
2. Portegies P. AIDS dementia complex: A review. J. Acquired Immune Defic. Syndr. 7:(Suppl 2):1994;S38-S49.
3. Schrager L.K., D'Souza M.P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. J. Am. Med. Assoc. 280:1998;67-71.
4. Gulik R.M., Mellors J.W., Halvir D., Eron J.J., Ganzalez C., McMahon D., Jonas L., Meilbohm A.M., Holder D., Scheif W.A., Condram J.H., Emini E.A., Isaacs R., Chodakewewitz J.A., Rich D.D. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine and lamivudine: 100-week follow-up. J. Am. Med. Assoc. 280:1998;35-41.
5. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T lymphotropic virus type III/Lymphadenopathy associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc. Natl. Acad. Sci. USA. 83:1986;1911-1915.
6. Balzarini J., Baba M., Pauwels P., Herdewijn P., de Clerq E. Antiretrovirus activity of 3′-fluoro and 3′-azido substituted pyrimidine and 2′,3′-dideoxynucleosides analogues. Biochem. Pharmacol. 37:1988;2847-2856.
7. Richman D.D. Antiviral therapy for HIV infection. Ann. Rev. Med. 42:1991;69-90.
8. Sandberg J.A., Slikker W. Jr. Developmental pharmacology and toxicology of anti-HIV therapeutic agents: Dideoxynucleosides. FASEB J. 9:1995;1157-1163.
9. Yarchoan R.R., Klecker W., Weinhold K.J., Markham P.D., Lyerly H.K., Durack D.T., Gelman E., Nusinhoff-Lehrman S., Blum R.M., Barry R.W., Shearer G.M., Fischl M.A., Mitsuya H., Gallo R.C., Collins J.M., Bolognesi D.P., Meyers C.E., Broder S. Administration 3′-azido, 3′-deoxythymidine an inhibitor of HTLV III/LAV replication to patients with AIDS and AIDS related complex. Lancet. i:1986;575-580.
10. Kamali F. Clinical pharmacology of zidovudine and other 2′,3′-dideoxynucleoside analogs. Clin. Invest. 71:1993;392-405.
11. Larder B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT). Science. 246:1989;696-699.
12. Jablonowski H., Arasteh K., Staszowski S., Ruf B., Stellbrink H.J., Schrappe M., Stoehr A., Haase W., Schomaker U., von Eisenhart-Rothe B. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine - German ddI trial group. AIDS. 9:1995;463-469.
13. Yarchoan R., Mitsuya H., Thomas R.V., Pluda J.M., Hartman N.R., Perno C.-F., Marszyk K.S., Allain J.-P., Johns D.G., Broder S. In vivo activity against HIV and favourable toxicity profile of 2′,3′-dideoxyinosine. Science. 245:1989;412-415.
14. Lambert J.S., Seidlin M., Reichman R.C., Plank C.S., Laverty M., Morse G.D., Knupp C., McLaren C., Pettinelli C., Valentine F.T., Dolin R. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS related complex. New Engl. J. Med. 322:1990;1333-1340.
15. Cooley T.P., Kunches L.M., Saunders C.A., Ritter J.K., Perkins C.J., McLaren C., McCaffrey R.P., Liebman H.A. Once daily administration of 2′,3′-dideoxyinosine (ddI) in patients with acquired immunodeficiency syndrome or AIDS related complex - Results of a Phase I trial. New Engl. J. Med. 322:1990;1341-1345.
16. Yarchoan R., Pluda J.M., Thomas R.V., Mitsuya H., Brouwers P., Wyvill K.M., Hartman N., Johns D.G., Broder S. Long term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS related complex. Lancet. ii:1990;526-529.
17. Drusano G.L., Yuen C., Morse G., Cooley T.P., Seidlin M., Lambert J.S., Liebman H.A., Valentine F.T., Dolin R. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in Phase I trials. Antimicrob. Agents Chemother. 36:1992;1280-1283.
18. Collins J.M., Klecker R.W. Jr., Kelley J.A., McCully C.L., Balis F.M., Poplack D.G. Pyrimidine dideoxynucleosides: Selectivity, penetration into cerebrospinal fluid. J. Pharmacol. Exp. Ther. 245:1988;466-470.
19. Anderson B.D., Hoesterey B.L., Baker D.C., Galinsky R.E. Uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats - Intravenous infusion studies. J. Pharmacol. Exp. Ther. 253:1990;113-118.
20. Tuntland R., Ravasco R.J., Al-Habet S., Unadkat J.D. Afflux of zidovudine and 2′,3′-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestina. Pharm. Res. 11:1994;312-317.
21. Barry M., Howe J.I., Ormesher S., Back D.J., Breckenridge A.M., Bergin C., Mulcahy F., Beeching N., Nye F. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with acquired immunodeficiency syndrome. Br. J. Clin. Pharmacol. 37:1994;421-426.
22. Larder B.A., Kohli A., Bloor S., Kemp S.D., Harrigan P.R., Schooly R.T., Lange J.M., Pennington K.N., St. Clair M.H. Human immunodeficiency virus type I - Drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxycytidine combination therapy - The protocol 34. 225-02 collaborative group. J. Virol. 70:1996;5922-5929.
23. Volberding P.A., Lagakos S.W., Koch M.A., Pettinelli C., Myers M.W., Booth D.K., Balfour H.H., Reichman R.C., Bartlett J.A., Hirsch M.S., Murphy R.L., Hardy W.D., Soeiro R., Fischl M.A., Bartlett J.G., Merigan T.C., Hyslop N.E., Richman D.D., Valentine F.T., Corey L. Zidovudine in asymptomatic human immunodeficiency virus infection - A controlled trial in persons with fewer than 500 CD4+ cells per cubic millimeter. New Engl. J. Med. 322:1990;941-949.
24. Pizzo P.A. Pediatric AIDS: Problems within patients. J. Infect. Dis. 161:1990;316-325.
25. Kawaguchi T., Ishikawa K., Seki T., Kazuhuko J. Ester prodrugs of zidovudine. J. Pharm. Sci. 79:1990;531-533.
26. Rappaport S.I., Ohno K., Pettigrew K.D. Drug entry into the brain. Brain Res. 172:1979;354-359.
27. Fischl M.A., Richman D.D., Grieco M.H., Gottileb M.S., Volberding P.A., Laskin O.L., Leedom J.M., Groopman J.E., Mildvan D., Schooley R.T., Jackson G.G., Durack D.T., King D.N. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. A double blind placebo controlled trial. New Engl. J. Med. 317:1987;185-191.
28. Richman D.D., Fischl M.A., Grieco M.H., Gottileb M.S., Volderding P.A., Laskin O.L., Leedom J.M., Groopman J.E., Mildvan D., Hirsch M.S., Jackson G.G., Durack D.T., Nusinoff-Lehrman S.N. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex: A double blind placebo controlled trial. New Engl. J. Med. 317:1987;192-197.
29. Klecker R.W., Collins J.M., Yarchoan R., Thomas R., Jenkins J.F., Broder S., Myers C.E. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido,3′-deoxythymidine: A novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin. Pharmacol. Ther. 41:1987;407-412.
30. Pizzo P.A., Eddy J., Falloon J., Balis F.M., Murphy R.F., Moss H., Wolters P., Brouwers P., Jarosinski P., Rubin M., Broder S., Rarchoan R., Brunetti A., Maha M., Nusinoff-Lehrman B.S., Poplack D.G. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. New Engl. J. Med. 319:1988;889-896.
31. E.V. Acosta, C.V. Fletcher, Agents for treating human immunodeficiency virus infection, Am. J. Hosp. Pharm. (1994) 51 and 251-2267.
32. Richman D.D. Resistance, drug failure and disease progression. AIDS Res. Hum. Retroviruses. 10:1994;901-905.
33. Shirasaka T., Kavliock M.F., Ueno T., Gao W.Y., Kojima E., Acaide M.L., Chokekijchai S., Roy B.M., Arnold E., Yarchoan R. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA. 92:1995;2398-2402.
34. Mayers D.L., Japour A.J., Arduino J.M., Hammer S.M., Reichman R., Wagner K.F., Chung R., Lane J., Crumpacker C.R., MacLeod G.X. Dideonucleoside resistance emerges with prolonged Zidovudine monotherapy. The RV43 study group. Antimicrob. Agents. Chemotherap. 38:1994;307-314.
35. Khoo H., Wilkins E. Controversies in anti-retroviral therapy in adults. J. Antimicrob. Ther. 35:1995;245-262.
36. Pantaleo G., Grazioci C., Demarest J.F., Butini L., Montroni M., Fox C.H., Orenstein J.M., Kotler D.P., Fauci A.S. HIV infection is active and progressive in lymphoid tissue during the clinically latent state of disease. Nature (London). 362:1993;355-358.
37. Kini G.D., Beadle J.R., Xie H., Aldern K.A., Richman D.D., Hostetler K.Y. Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV. Antiviral Res. 36:(1):1997;43-53.
38. Manouilov K.K., Xu Z.S., Boudinot F.D., Schinazi R.F., Chu C.K. Lymphatic targeting of anti-HIV nucleosides: distribution of 2′,3′-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice. Antiviral Res. 3:1997;91-99.
39. Cook C.S., Karabatsos P.J., Schoenhard G.L., Karim A. Species-dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavailability of active SC-48334. Pharm. Res. 8:1995;1158-1164.
40. Driscoll J.S., Siddiqui M.A., Ford H. Jr., Kelley J.A., Roth J.S., Mitsuya H., Tanaka M., Marquez V.E. Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2′-beta-fluoro-2′,3′-dideoxyinosine. J. Med. Chem. 39:(8):1996;1619-1625.
41. P. DeMaranda, T.C. Burnette, S.S. Good, Disposition and pharmacokinetics of the anti-viral drug 3′-azido,3′-deoxythymidine (Retrovir) in monkeys and rats, 27th Interscience Conference on Antiviral Agents and Chemotherapy, New York, October 4-7, Abstract #378, 1987, p. 162.
42. Chu C.K., Bhadti V.S., Doshi K.J., Etse J.T., Gallo J.M., Boudinot F.D., Schinazi R.F. Brain targeting for anti-HIV nucleosides: Synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-azido,3′-dideoxythymidine. J. Med. Chem. 33:1990;2188-2192.
43. Tsuzuki N., Hama T., Kawada M., Hasui A., Konishi R., Shiwa S., Ochi Y., Futaki S., Kitagawa K. Adamantane as a brain directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with 1-adamantane moiety. J. Pharmaceut. Sci. 83:1994;481-484.
44. Hostetler K.Y., Kini G.D., Beadle J.R., Aldern K.A., Gardner M.F., Border R., Kumar R., Barshak L., Sridhar C.N., Wheeler C.J., Richman D.D. Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro. Antiviral Res. 1-2:1996;59-67.
45. Wirtz K.W. Transfer of phospholipids between membranes. Biochim. Biophys. Acta. 344:1974;95-117.
46. Balagopala M.I., Ollapally A.P., Lee H.J. Synthesis and anti-HIV activity of steroidal prodrugs of 3′-azido-3′-deoxythymidine (AZT). Cell. Mol. Biol. 41:(Suppl 1):1995;S1-S7.
47. Yatvin M.B., Li W., Stowell M.B.H., Gallicchio V.S., Shaw W.A., Burgess S.W. Increased intracellular uptake, half life, improved antiviral action, decreased marrow toxicity and central nervous system uptake and retention by a prodrugs of AZT. AIDS Monograph Band 5. 1996;278-281 Economed Vertagsgesellschaft AG & Co. KG, Landsberg/Loch, Germany.
48. Kozak S.L., Kabat D. Ping-pong amplification of a retroviral vector achieves high level gene expression: Human growth hormone production. J. Virol. 64:1990;3500-3508.
49. Barlkis E.W., Yatvin M.B. The life cycle of retroviruses: the influence of hyperthermia and membrane organization. Membrane Interactions of HIV. 1992;215-236.
50. Hostetler K.Y., Carson D.A., Richman D.D. Phosphatidyl-azidothymidine: Mechanism of antiretroviral action in CEM cells. J. Biol. Chem. 266:1991;11714-11717.
51. Furman P.A., Fyfe J.A., Clair M.H., Weinhold K., Rideout J.L., Freeman G.A., Lehrman S.A., Bolognesi D.P., Broder S., Mitsuya H., Barry D.W. Phosphorylation of 3′azido 3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA. 83:1986;8333-8337.
52. Hostetler K.Y., Richman D.D., Carlson D.A., Stuhmiller L.M., van Wijk G.M.T., van den Bosch H. Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3′-deoxy thymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3′-deoxythymidine. Antimicrob. Agents Chemother. 36:1992;2025-2029.